Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14262185 | 0.85 | LMNA (0.48) | LMNATSHR | |
| SCHEMBL6562134 | 0.83 | LMNA (1.00) | LMNATSHRPOLBKDM4ETDP1 | |
| SCHEMBL23008767 | 0.78 | LMNA (0.64) | LMNATSHRKDM4E | |
| SCHEMBL8739738 | 0.78 | — | — | |
| SCHEMBL836383 | 0.75 | LMNA (0.82) | LMNATSHRPOLBKDM4ETDP1 | |
| SCHEMBL15298754 | 0.75 | LMNA (0.82) | LMNATSHRPOLBKDM4ETDP1 | |
| SCHEMBL14516809 | 0.74 | LMNA (0.78) | LMNATSHRPOLBKDM4ETDP1 | |
| SCHEMBL24347595 | 0.74 | LMNA (0.78) | LMNATSHRPOLBKDM4ETDP1 | |
| SCHEMBL10064431 | 0.73 | — | — | |
| SCHEMBL12989977 | 0.72 | LMNA (0.75) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | LMNA 4552/4885TSHR 116/4885POLB 2483/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | LMNA 4170/4885TSHR 2566/4885POLB 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.